COVERAGE LOG
Denali Therapeutics Inc. · SEC filing date March 25, 2026
Denali Therapeutics Inc. (CIK: 0001714899) announced on March 25, 2026, the U.S. FDA accelerated approval of AVLAYAH™ (tividenofusp alfa-eknm) for the treatment of neurologic manifestations in pediatric patients with Hunter syndrome (MPS II), marking the company's first medicine…
This page is one entry in NexusAlert's public Coverage Log. The date is the SEC filing date — the date the filing was filed with the SEC. The summary is what NexusAlert wrote when it read the filing, shown unedited. Rows are never silently rewritten after they appear in the log. See the full log →
No Investment Advice: The analysis, data, and information provided by Nexus Alert are generated by Artificial Intelligence (AI) for general informational and educational purposes only. This content does not constitute financial, investment, legal, or tax advice. It is not an offer or solicitation to buy or sell any security or financial instrument.
Accuracy and Risks: While we strive for accuracy, AI-generated content may contain errors, omissions, or inaccuracies. Financial markets are inherently volatile and past performance is not indicative of future results. The algorithms used do not account for your personal financial goals, risk tolerance, or time horizon.
Consult a Professional: You should not make any investment decisions based solely on this information. We strongly recommend that you conduct your own independent research and consult with a qualified, licensed financial advisor or professional before making any financial commitments.
Limitation of Liability: Nexus Alert and its affiliates shall not be held liable for any financial losses or damages resulting from the use of or reliance on the information provided by the Service.
Want these as they happen? Search every filing free, or start a Pro trial.
Start free Pro trial →